Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trevena Inc TRVN

Healthcare Biotechnology
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).


OTCPK:TRVN - Post by User

Trevena Inc
Bullboard Posts
User Avatar Image
(14)
•••
Post by GolongGekkoon Feb 17, 2017 1:44pm
68 Views
Post# 25862284

CARA vs TRVN . . .

CARA vs TRVN . . .Interesting comparison with these two Bio plays.  Very similar in structure and focus.

Cara has 1/2 the shares out, ( 27mil) but is twice the price. Both CARA and TRVN are quite volitile and have similar trading patterns. CARA has 4mil SHORT at present and can flux SP wise $2 in a day. CARA's pain play is different from Trevena, but both may have success in their own lanes.

In the Gekko's IMHO, I see TRVN as a stronger candidate going forward. But both look to be a TAKEOUT candidate if their trials and FDA approvals work out.

This BIO sector is MR. GEKKO's WILD RIDE. and we all know The GEKKO is a CRAFTY one. I shall GOLONG here . .. The NEW War cry . . . OLICERIDINE or TAKEOUT!!!

Best GG
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities